On the heels of an Eli Lil­ly deal, NextCure’s hot hand in I/O at­tracts a $93M trans-Pa­cif­ic ven­ture round

Last week Eli Lil­ly showed their faith in NextCure by fronting an im­muno-on­col­o­gy col­lab­o­ra­tion with $40 mil­lion in up­front and eq­ui­ty cash. This week the biotech is com­ing out with a $93 mil­lion raise to help il­lus­trate how trendy I/O re­mains in ven­ture cir­cles — es­pe­cial­ly if you promise to break some new ground in the field.

Ex­perts in ex­plor­ing the sur­face of cells in the de­vel­op­ment of new can­cer ther­a­pies, their lead drug is in pre­clin­i­cal de­vel­op­ment. NC318 tar­gets S15, which the com­pa­ny be­lieves helps myeloid cells sur­vive and thrive, while tap­ping down on the T cell re­spons­es that are now be­ing dri­ven by a host of drugs in the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.